Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Cell Communication and Signaling

Volumn 13, Issue 1, 2015, Pages

  Olsen, Oddrun Elise ^a   Wader, Karin Fahl ^b   Hella, Hanne ^a   Mylin, Anne Kærsgaard ^c   Turesson, Ingemar ^d   Nesthus, Ingerid ^e   Waage, Anders ^a,b   Sundan, Anders ^a   Holien, Toril ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Activin A; BMP; Bone morphogenetic proteins; Follistatin; Myeloma; Receptor

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR 2A; ACTIVIN RECEPTOR 2B; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; DRUG RECEPTOR; PROTEIN ALK2; UNCLASSIFIED DRUG; ACTIVIN; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II-A; ACVR1 PROTEIN, HUMAN; ACVR2B PROTEIN, HUMAN; FOLLISTATIN;

ARTICLE; BINDING AFFINITY; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; METABOLISM; MULTIPLE MYELOMA; TUMOR CELL LINE;

ACTIVIN RECEPTORS, TYPE I; ACTIVIN RECEPTORS, TYPE II; ACTIVINS; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; FOLLISTATIN; HUMANS; MULTIPLE MYELOMA; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION;

EID: 84931048536     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-015-0104-z     Document Type: Article

References (20)

1. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003;12:817-28.
2. Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG, et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J. 2007;21:2949-60.
3. Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D, et al. Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014;28:951-4.
4. Sozzani S, Musso T. The yin and yang of Activin A. Blood. 2011;117:5013-5.
5. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010;107:5124-9.
6. Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. 2012;23:2681-6.
7. Walton KL, Makanji Y, Harrison CA. New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol. 2012;359:2-12.
8. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 1993;75:671-80.
9. Rejon CA, Hancock MA, Li YN, Thompson TB, Hebert TE, Bernard DJ. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells. Cell Signal. 2013;25:2717-26.
10. Hemmati-Brivanlou A, Kelly OG, Melton DA. Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell. 1994;77:283-95.
11. Sideras P, Apostolou E, Stavropoulos A, Sountoulidis A, Gavriil A, Apostolidou A, et al. Activin, neutrophils, and inflammation: just coincidence? Semin Immunopathol. 2013;35:481-99.
12. Holien T, Vatsveen TK, Hella H, Rampa C, Brede G, Groseth LA, et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. 2012;26:1073-80.
13. Olsen OE, Wader KF, Misund K, Vatsveen TK, Ro TB, Mylin AK, et al. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer J. 2014;4, e196.
14. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65-74.
15. Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 2004;23:3024-32.
16. Holien T, Sundan A. The role of bone morphogenetic proteins in myeloma cell survival. Cytokine Growth Factor Rev. 2014;25:343-50.
17. Lavery K, Swain P, Falb D, Alaoui-Ismaili MH. BMP-2/4 and BMP-6/7 Differentially Utilize Cell Surface Receptors to Induce Osteoblastic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells. J Biol Chem. 2008;283:20948-58.
18. Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165:814-23.
19. Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408-14.
20. Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood. 2001;97:516-22.